Understanding Early and Ongoing Treatment Utilization of Palbociclib in a US Community Oncology Setting

Study type

• Study topic:
  Disease /health condition

  Human medicinal product
• Study type:
  Non-interventional study
• Scope of the study:
  Drug utilisation
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Other
• Non-interventional study design, other:
  Descriptive, retrospective longitudinal study

Study drug and medical condition

• Name of medicine:
  IBRANCE
• Medical condition to be studied:
  Breast cancer metastatic

Population studied

• Short description of the study population:
  Female breast cancer patients greater than or equal to 18 years of age who initiated Palbociclib between February 1, 2015 and January 31, 2016.
• Age groups:
  Adults (18 to < 46 years)

  Adults (46 to < 65 years)

  Adults (65 to < 75 years)

  Adults (75 to < 85 years)

  Adults (85 years and over)
• Special population of interest:
  Other
• Special population of interest, other:
  Metastatic breast cancer patients
• Estimated number of subjects:
  1500

Study design details

• Main study objective:
  To describe the demographic and clinical characteristics of patients newly initiating Palbociclib therapy, To describe early treatment utilization of patients newly initiating Palbociclib therapy including time to discontinuation.
• Data analysis plan:
  This study is a longitudinal, retrospective observational study. It is descriptive in nature.

Documents

Study results

A5481062 Abstract

Study report

A5481062